Search results
Results From The WOW.Com Content Network
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
Pfizer and Moderna vaccines are both safe and have similar effectiveness at preventing COVID-19 illness. Clinical trial data when they were first released in December 2020 showed 95% efficacy for ...
The COVID-19 mRNA vaccines from Moderna and Pfizer–BioNTech had short-term efficacy rates of over 90 percent against the original SARS-CoV-2 virus. Prior to mRNA, drug trials on pathogens other than COVID-19 were not effective and had to be abandoned in the early phases of trials. The reason for the efficacy of the new mRNA vaccines is not clear.
[353] [354] [355] Aiming for a realistic population vaccination coverage rate of 75%, and depending on the actual basic reproduction number, the necessary effectiveness of a COVID-19 vaccine is expected to need to be at least 70% to prevent an epidemic and at least 80% to extinguish it without further measures, such as social distancing. [356]
Earlier this year, Moderna’s longer-term trial analysis revealed a faster decline in the effectiveness of its RSV vaccine. Follow-up data from Phase 3 mRNA-1345 Trial ReSViNET suggests the ...
Coronavirus stocks played a massive part in the stock market’s 2020 narrative. However, in 2021, so far, Moderna (MRNA) has continued last year’s performance. Shares are already up 66% this ...
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
The Food and Drug Administration (FDA) has approved Moderna’s RSV mRNA vaccine for adults older than 60 years. The approval makes RSV the second disease for which an mRNA vaccine has been ...